• Integrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis
  • DRAGEN™ pipelines optimized for IDT custom hybrid capture panels enable accurate, efficient, variant detection
  • The DRAGEN Somatic for IDT Custom Panels feature a new, low-quality FFPE mode to analyze challenging samples

Integrated DNA Technologies (IDT), a Danaher company and global leader in genomics, today announced a strategic collaboration with Illumina, Inc. (NASDAQ:ILMN) to enable a DRAGEN™ secondary analysis pipeline for IDT xGen™ FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. By connecting IDT's library prep with Illumina's DRAGEN secondary analysis platform, researchers can reduce downstream burden and accelerate the path from sequencing to insight with greater speed and consistency.